FDA Approved: IMJUDO — Supplemental Application (AstraZeneca Pharmaceuticals LP)

View source ↗

Summary

The FDA approved a supplemental application for IMJUDO (tremelimumab) from AstraZeneca.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Malignant Pleural Mesothelioma
• Melanoma

Drugs mentioned

• IMJUDO (TREMELIMUMAB)

Snippet

SUPPL AP for IMJUDO (TREMELIMUMAB)